If you ask Adam Grossman what his commercial biopharmaceutical company does, the response is simple.
“We make healthy immune systems in a bottle,” he said.
Of course what ADMA Biologics does in its Boca Raton manufacturing facility has plenty of complicated science behind it. But the founder, director, president and CEO of the company explained what the company is doing in simple terms.
ADMA takes plasma donations from healthy people and turns that plasma into therapeutic products for the treatment of immunodeficient patients at risk for infection and the prevention of certain infectious diseases.
Recently, ADMA was named Company of the Year by BioFlorida, in recognition of ADMA’s significant achievements over the past year.
ADMA does a lot of work for patients with Primary Immune Deficiency Disease. About half of the people living in the United States with the disease receive a monthly infusion of a drug created by ADMA.
The technical name for that, “healthy immune system in a bottle” is an intravenous immune globulin. Patients receive an infusion monthly, which helps them fight off infectious diseases and allow them to lead productive lives, Grossman said.
ADMA has FDA approval on two of its products and is a publicly traded company on NASDAQ. The company’s total revenues for the third quarter totaled $7.2 million, a 71 percent increase from the year before.
Grossman launched the business in 2004 and took over the Boca facility about two and a half years ago.
He said he bought the Boca plant knowing it needed work and he has turned it around and brought the number of employees from about 130 to now 300 with plans to expand and grow even more. A majority of the 300 employees work at the Boca campus.
“It is our pleasure to award ADMA as the BioFlorida Company of the year based upon all of their recent regulatory, financial and growth achievements,” said Nancy Bryan, President and Chief Executive Officer of BioFlorida. “ADMA’s growth is a testament to the business opportunities available in Florida, where life science companies can achieve great things with our talent pool and resources.”
Grossman said he his humbled by the recognition the company received from BioFlorida, which is the voice of Florida’s life science industry, representing 6,200 establishments and research organizations in the biopharmaceutical, medical technology, HealthIT and bioagriculture sectors that collectively employ just over 87,000 Floridians.
“It really makes our staff feel good,” he said. “It’s really quite a feat. We took over this company that was in need of some life support.”
And he said knowing that he is employing people while helping people with life changing medication, is what is fulfilling to him.
“Across the country we are looking at adding a number of jobs,” he said. “It’s exciting to be in that position while you are helping patients.”